Renasight™ Genetic Kidney Panel
Genetic test analyzing 300+ genes linked to kidney disease, helping identify inherited causes of CKD, nephrolithiasis, and related renal conditions.
Accessed through the Renasight™ Sponsored Testing Program•Sponsored by Vertex Pharmaceuticals•Performed by Natera
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
This program offers no-cost Renasight™ testing for eligible patients of African ancestry with chronic kidney disease. It supports early identification of APOL1 risk variants associated with APOL1-mediated kidney disease (AMKD). Providers can use results to inform diagnosis, guide management decisions, and determine whether genetic factors may underlie renal decline.
When to consider this test
Patient selection
- Providers may order sponsored testing for patients who meet all of the following:
- Patient self-identifies as African American, African, or Afro-Caribbean
- Patient has a confirmed diagnosis of non-diabetic CKD
- Patient has not undergone dialysis or kidney transplantation
Workflow
How to use this program
- 1
Discuss Eligibility
Review program criteria with patients who may benefit and confirm they meet all eligibility requirements. Obtain informed consent before proceeding.
- 2
Order Test
Submit the Renasight™ requisition and attestation forms (both required). Collect a blood or buccal specimen using a Renasight™ kit, and return it using the prepaid label.
- 3
Review Results
Access results in ~3 weeks and incorporate findings—including APOL1 risk status—into the patient’s diagnostic assessment and care plan.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Natera, a CLIA-certified laboratory (CLIA 05D1082992) and College of American Pathologists (CAP) certified laboratory (CAP 8737934). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Who is eligible for the Vertex-Sponsored Renasight™ Program?
Patients must meet all of the following:
• Self-identify as African American, African, or Afro-Caribbean
• Have non-diabetic chronic kidney disease
• Have no history of dialysis or kidney transplant
What is the purpose of this testing?
The program focuses on evaluating APOL1 variants associated with APOL1-mediated kidney disease (AMKD). Genetic testing is the only way to confirm AMKD, making Renasight™ useful for diagnosis, risk stratification, and clinical discussions.
Which genes are analyzed?
The sponsored panel assesses the full Renasight™ renal genetic testing panel, including APOL1, plus additional kidney-disease genes depending on the ordering option selected.
What sample types can be used?
Blood or buccal swab samples collected using a Renasight™ kit.
How do I order testing?
Providers submit both:
• A Renasight™ requisition form
• The required attestation form
Samples are shipped using prepaid labels provided with the kit.
When are results available?
Results are typically posted to your Natera portal in approximately 3 weeks.
Is genetic counseling available?
Yes. Natera’s Renal Genetic Counselors (RGCs) provide complimentary post-test counseling. RGCs can:
• Help you interpret Renasight™ results
• Provide patients with individualized result review
• Explain disease inheritance patterns
• Notify providers of variant reclassifications or updated results
• Supply post-session notes for documentation
Does participation commit the provider or patient to any treatment pathway?
No. The program does not require or promote any particular therapy.
See an issue with this program?